The ACC initiative, established in 2011, represents a multi-million-dollar commitment uniting some of the most influential players in cancer research and drug development. Industry partners span a formidable roster, including AbbVie, Amgen, ARIAD, Celgene, Eli Lilly and Company, Genentech, Gilead, Merck, Novartis, Pfizer, and Takeda Pharmaceuticals. This unique partnership underlines the intensified focus on collaborative innovation necessary to combat cancer’s complex molecular and clinical landscape. The synthesis of academic insight with the drug discovery prowess of industry exemplifies a new paradigm in oncology research.

Opening the symposium, Damon Runyon President and CEO Yung S. Lie, PhD, alongside Damon Runyon Board member and BioNTech’s President of Research and Development Richard B. Gaynor, MD, and Amgen’s Executive Vice President of Research and Development James Bradner, MD, set an ambitious tone. Dr. Bradner, himself an alumnus of the Damon Runyon-Rachleff Innovator program, famously dubbed Damon Runyon a “triple-A team,” emphasizing how the foundation nurtures some of the most courageous and innovative scientific talents entering the biopharmaceutical sector.

The symposium featured several cutting-edge presentations from Damon Runyon-supported scientists, who are delving into the intricacies of cancer genomics and gene expression regulation. Mark Yarmarkovich, PhD, Lucas Farnung, PhD, Mary M. Mullen, MD, and Ziyang Zhang, PhD, each shared advances that aim to delineate the molecular signatures of various cancers to design highly precise, targeted therapies. Their work exemplifies the shift from broad-spectrum chemotherapeutics to tailored interventions that exploit tumor-specific vulnerabilities.

A keynote address delivered by Anna Farago, MD, PhD, Vice President of Early Development in Oncology at Amgen, and Julie Bailis, PhD, a former Damon Runyon Fellow and current Vice President of Oncology Research at Amgen, underscored the essential dialogue between preclinical data and clinical trial findings. Dr. Bailis articulated the tremendous value of iterative feedback loops between bench and bedside, a relationship imperative for refining therapeutic candidates and accelerating their journey through development pipelines.

Further illuminating the challenging landscape of difficult-to-treat malignancies, Damon Runyon investigators Megan A. Morrissey, PhD, Srivatsan Raghavan, MD, PhD, and Jonathan Chou, MD, PhD, discussed innovative approaches in combatting refractory cancers, including pancreatic adenocarcinoma. These types of malignancies, notorious for their resistance to conventional therapies and poor prognosis, demand novel therapeutic paradigms informed by deep mechanistic insights, such as targeting tumor microenvironmental factors or exploiting unique metabolic dependencies.

The afternoon session’s fireside chat, expertly moderated by Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences, brought together top translational oncology leaders—Jennifer Lauchte, MD (Novartis), Alex R. Shoemaker, PhD (AbbVie), and Louis Vermeulen, MD, PhD (Genentech). Their candid discussion highlighted the mechanics of successful collaboration in the drug development arena. Dr. Lauchte stressed the necessity of integrating multidisciplinary teams encompassing clinical trialists, molecular biologists, and medicinal chemists to generate comprehensive insights, avoiding siloed approaches that impede progress.

This symposium exemplifies the tangible benefits when academia and industry synchronize efforts to tackle cancer’s complexity. Dr. Lie and Margaret Faul, PhD, Vice President of Drug Substance Technologies and Site Head of Amgen Massachusetts, concluded the day by emphasizing the value of cross-disciplinary collaboration, noting that the Accelerating Cancer Cures initiative models how such partnerships can spur innovative therapeutic breakthroughs.

The ACC program’s strategy is rooted in empowering early-career clinical investigators by providing them with the funding and collaborative networks necessary to pursue high-risk, high-reward translational research. The iterative, bidirectional communication fostered between scientists, clinicians, and industry experts accelerates the identification of actionable biomarkers, validation of therapeutic targets, and the optimization of drug candidates. The promise of this synergy lies in shortening the timeline from scientific discovery to effective patient treatment.

Underlying the discussions at the symposium is an appreciation for the genomic and proteomic heterogeneity that defines malignancies. The presentations underscored the importance of leveraging next-generation sequencing technologies, CRISPR-based functional genomics, and sophisticated computational biology tools to unravel cancer’s molecular complexity. Such approaches enable the development of precision oncology strategies that account for tumor evolution, microenvironmental influences, and immune evasion mechanisms.

Moreover, the symposium shed light on the growing trend of integrating novel modalities, including bispecific antibodies, cell therapies, and targeted protein degraders in cancer therapeutics. These modalities, often emerging from deep academic research programs, require robust translational frameworks to ensure their effective clinical application. The ACC consortium’s commitment to facilitating these translational bridges is vital for capitalizing on these groundbreaking modalities.

In summary, the 2026 Accelerating Cancer Cures Research Symposium not only highlighted the impressive scientific advances driven by Damon Runyon scientists but also exemplified the power of collaborative ecosystems that unite academic ingenuity with industrial development capacity. With relentless dedication and strategic partnerships, the ambitions to transform cancer from a fatal diagnosis into a manageable condition have never been closer to fruition. This event stands as a beacon of hope and an illustration of how concerted collective efforts can accelerate the delivery of transformative cancer therapies to patients worldwide.

Subject of Research: Translational cancer research focused on accelerating discovery and development of targeted therapies through collaboration between academia and industry.

Article Title: Accelerating Cancer Cures: The 2026 Damon Runyon Symposium Sparks Dynamic Innovation in Oncology Therapeutics

News Publication Date: March 24, 2026

Web References:
– https://www.damonrunyon.org/
– https://www.amgen.com/
– https://www.novartis.com/
– https://www.genentech.com/
– https://www.abbvie.com/

Keywords: cancer genomics, targeted therapies, translational research, clinical innovation, collaboration, Damon Runyon, Accelerating Cancer Cures, oncology, pharmaceutical industry, molecular oncology, precision medicine, drug development

The study’s primary focus was to investigate how talazoparib, a potent PARP inhibitor, can amplify the anti-angiogenic properties of quinacrine, which is traditionally viewed as an anti-malarial drug but has recently gained attention for its cancer-fighting capabilities. The researchers observed that the administration of talazoparib significantly disrupted the functions of critical chromatin remodelers, including P300 and GCN5. These remodelers play pivotal roles in regulating gene expression and, by extension, the behavior of cancer cells.

The research team employed patient-derived oral cancer stem cells for their experiments, emphasizing the relevance of their findings to real-world clinical settings. This model closely mimics the tumor microenvironment found in patients, allowing for more accurate assessments of how these drugs interact within embryonic settings. The implications of using patient-derived cells cannot be overstated; they provide a more direct correlation to potential patient outcomes compared to traditional cancer cell lines.

One of the most significant discoveries from this research revolves around the role of P300 and GCN5. These chromatin remodelers are integral to the transcriptional regulation of genes responsible for cellular proliferation, survival, and metastasis. Talazoparib’s ability to disrupt their function opens up new avenues for refining cancer treatment strategies. This finding suggests that not only can talazoparib inhibit DNA repair mechanisms in cancer cells, but it can also alter the expression of key oncogenes through epigenetic modulation.

The combination therapy proposed in the study paves the way for a dual-hit approach to combatting cancer. Traditional therapies often become less effective as cancer cells acquire resistance, but by using a combination of agents with differing mechanisms of action, the likelihood of maintaining efficacy increases substantially. This strategy could mitigate the challenges posed by tumor heterogeneity, a common hurdle in cancer treatment, allowing for a more comprehensive attack on the cancer landscape.

Additionally, the importance of addressing angiogenesis—the process by which new blood vessels form to supply tumors with the nutrients they need to grow—cannot be overlooked. By enhancing quinacrine’s anti-angiogenic effects, talazoparib not only tackles the cancer cells directly but also constricts the vascular infrastructure that supports tumor growth and metastasis. This dual mechanism may yield a more potent therapeutic effect than either agent could achieve alone.

The study advances a significant scientific narrative that challenges existing paradigms in cancer treatment. Researchers are increasingly recognizing the need for combination therapies that exploit unique drug properties and modes of action. The findings strongly advocate for further investigation into drug combinations that transcend traditional boundaries and engage with personalized medicine approaches, tailoring therapies to the genetic and epigenetic context of individual tumors.

Of particular interest is the potential to translate this combination therapy to clinical trials. Given the promising preliminary results showcased in their study, the authors encourage the initiation of clinical investigations to assess the safety and efficacy of this therapeutic regimen. Such trials could fundamentally shift treatment paradigms for oral cancer patients, potentially leading to improved survival rates and quality of life metrics.

Moreover, understanding the molecular dynamics underpinning these interactions can yield insights that extend beyond oral cancer into other malignancies. The involvement of P300 and GCN5 is not unique to oral cancer; their roles are implicated in numerous tumor types, suggesting that this research may have broader implications in oncological therapeutics.

It is also crucial to point out the regulatory considerations that will be necessary as this research moves towards the clinic. The process of obtaining approval for new combination therapies can be lengthy and complex. However, the potential for improved patient outcomes provides a compelling argument for expedited pathways in regulatory processes, especially when dealing with treatments for aggressive cancers.

In summary, the collaboration of talazoparib and quinacrine presents a promising strategy to enhance anti-cancer efficacy in oral cancers through novel mechanisms involving chromatin remodeling. The study not only sheds light on the intricate molecular relationships underlying cancer resilience but also propels the field towards more personalized, effective treatment approaches.

The future of cancer treatment lies in discoveries like these, driving the field to adapt and innovate in the face of persistent challenges. By unearthing novel connections between established drugs and emerging concepts in cancer biology, researchers can forge paths toward transformative therapeutic strategies that promise to change the landscape of treatment for cancer patients worldwide.

Subject of Research: Combination therapy of talazoparib and quinacrine in oral cancer treatment.

Article Title: Talazoparib enhances the anti-angiogenic potential of quinacrine through the deregulation of P300 and GCN5 chromatin remodelers in patient-derived oral cancer stem cells.

Article References:

Das, C., Paul, S., Bhal, S. et al. Talazoparib enhances the anti-angiogenic potential of quinacrine through the deregulation of P300 and GCN5 chromatin remodelers in patient-derived oral cancer stem cells. 3 Biotech 16, 49 (2026). https://doi.org/10.1007/s13205-025-04670-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04670-2

Keywords: Talazoparib, Quinacrine, Oral Cancer, Chromatin Remodelers, P300, GCN5, Anti-Angiogenic, Cancer Stem Cells.

The existence of synapses—specialized junctions that enable communication between neurons—has historically been thought to occur exclusively within the nervous system and, more recently, within brain tumors originating from neural tissue. This study disrupts that conventional notion by demonstrating that a lung cancer, originating far from the nervous system, can physically and functionally wire itself into neuronal circuits. Such integration underscores a profound level of cancer-host interaction, suggesting that tumors may co-opt the body’s own communication systems to enhance their proliferative capabilities and resist treatments.

Starting with a comprehensive genetic analysis, the investigators identified a subset of genes implicated in synapse formation that are aberrantly expressed in SCLC cells. This discovery paved the way for detailed imaging and electrophysiological studies using both cell cultures and sophisticated mouse models carrying allografts of SCLC. These experiments visually and functionally confirmed the presence of synaptic contacts where lung cancer cells connected with nearby neurons, effectively creating a hybrid interface facilitating bidirectional communication.

The senior authors emphasized the startling extent to which SCLC cells “innervate” and manipulate their microenvironment. Professor Matteo Bergami, a principal investigator at the University of Cologne, noted the remarkable adaptability of these cancer cells in forming synaptic connections with diverse neuronal populations, including sensory and cortical neurons. This plasticity suggests a dynamic and aggressive strategy whereby cancer cells exploit neural inputs to fuel their malignant progression, potentially explaining why SCLC is notorious for rapid growth and early metastasis to the brain.

Central to their findings was the identification of two key neurotransmitters, glutamate and gamma-aminobutyric acid (GABA), which mediate signaling at the neuron-cancer synapses. These neurotransmitters are fundamental to normal brain function, regulating excitatory and inhibitory signals, respectively. The presence of functional glutamate and GABA signaling platforms in SCLC cells indicates that these malignancies do not merely form structural contacts but actively engage in neurochemical communication, co-opting signaling pathways to enhance their survival and proliferation.

Experimental interventions disrupting glutamate signaling yielded promising preclinical results. Pharmacological blockade of this pathway significantly reduced tumor burden in animal models and extended their survival, marking a crucial step toward translating this knowledge into therapeutic interventions. The research team highlighted that targeting neurotransmitter signaling in SCLC offers an innovative route for treatment, possibly in combination with existing chemotherapies, thus providing a multipronged approach to combat resistant cancer forms.

The implications of these findings extend beyond SCLC. The concept that peripheral tumors might establish synaptic-like interactions with neurons challenges current paradigms in oncology and neurobiology, raising the possibility that other cancers might similarly exploit neural circuits. This realization calls for a broader examination of cancer-neuron crosstalk in various malignancies and may spearhead the development of a new class of neuro-targeted oncological therapies.

Collaborating across institutions in Germany, Belgium, and the United States, the research effort was spearheaded by scientists from the University of Cologne, University Hospital Essen, University of Göttingen, Heinrich Heine University Düsseldorf, and prominent partners in Munich, Antwerp, and Stanford. This extensive cooperation was critical for integrating cutting-edge genomic analysis, live-cell imaging, electrophysiology, and in vivo studies, providing a comprehensive portrait of the molecular and functional mechanisms underpinning cancer-neuron synapses.

While the molecular players facilitating synapse formation remain under active investigation, the study suggests that SCLC cells possess molecular machinery reminiscent of neuronal cells, including synaptic scaffolding proteins and receptors. Understanding these components at a molecular level will be essential for devising strategies to selectively disrupt cancer-neuron synapses without damaging normal brain function, a challenge that demands precision oncology coupled with neurobiology insights.

Moreover, the revelation that sensory and cortical neurons can differentially influence SCLC cell proliferation underscores the heterogeneity and complexity of the tumor microenvironment. It posits that the nervous system’s role in cancer progression is nuanced, relying on local circuitry as well as systemic neural influences. Such insights may redefine how metastasis, particularly to the central nervous system, is studied and managed, as the brain’s microenvironment can be uniquely manipulated by invading tumor cells through synaptic integration.

The therapeutic potential of repurposing existing neurotransmitter-blocking drugs, some already approved for neurological disorders, offers a rapid translational pathway. Meanwhile, novel molecules specifically designed to target the unique molecular signatures of cancer synapses are a promising avenue for next-generation therapies. Importantly, this approach aligns with the increasing recognition of tumor microenvironment targeting as a strategy to overcome drug resistance and improve patient outcomes.

This transformative research not only amplifies our understanding of tumor biology but also illuminates the intimate, previously unappreciated dialogue between cancer and the nervous system. It charts a future where cancer may be combated not only through targeting the cancer cells themselves but also by severing the rogue conversations they hold with neural networks, ultimately starving tumors of the inputs they hijack for survival.

In conclusion, the discovery of functional synapses between lung cancer cells and neurons is a landmark advancement in cancer research. It points to an uncharted frontier that bridges neuroscience and oncology, igniting hope for novel interventions that could dramatically alter the prognosis of small-cell lung cancer, a disease that has long defied existing therapies. As researchers continue to unravel the intricacies of neuron-cancer crosstalk, the prospects of more effective and tailored treatments come into clearer view.

Subject of Research: Animals
Article Title: Functional synapses between neurons and small-cell lung cancer
News Publication Date: 10-Sep-2025
Web References: http://dx.doi.org/10.1038/s41586-025-09434-9
Image Credits: Abdulla Chihab, Kristiano Ndoci and Felix Gaedke | University of Cologne
Keywords: small-cell lung cancer, neuron-cancer synapses, glutamate signaling, GABA, tumor microenvironment, neurotransmitter blockade, synapse formation, cancer-neuron communication, targeted therapy, metastasis, experimental mouse model, cancer biology

Roca-Cusachs, alongside his postdoctoral researcher Mamatha Nijaguna, is embarking on a pioneering endeavor dubbed the INTROPY project. This innovative project is poised to investigate the inhibition of mechanotransduction as a novel therapeutic avenue for cancer treatment. Mechanotransduction refers to the intricate process through which cells convert mechanical stimuli into biochemical signals, fundamentally influencing several biological processes, including embryonic development, tumor progression, and wound healing. The concept is particularly relevant within the context of cancer, where mechanical alterations in the microenvironment can significantly influence disease progression and treatment efficacy.

Among the primary mechanistic changes prompted by tumor activity is the stiffening of surrounding tissues, a condition commonly observed in cancers that accelerates tumor growth. Roca-Cusachs and his team have made significant strides in identifying a crucial protein interaction involved in mechanotransduction. By pinpointing this interaction, they are advocating for a therapeutic strategy aimed at inhibiting these specific proteins, thereby disrupting the mechanotransduction pathways that contribute to cancer progression.

To support their hypothesis, Roca-Cusachs and Nijaguna’s team has conducted extensive screening tests and identified six small molecules that demonstrate considerable potential in targeting these proteins. The forthcoming phase of the INTROPY project will focus on validating these findings, rigorously demonstrating the therapeutic efficacy of these compounds using in vitro assays and mouse models. Success in this endeavor could yield groundbreaking advancements in cancer therapy, presenting new opportunities for intervention in the disease.

The implications of the INTROPY project extend far beyond conventional therapeutic strategies. The potential for this innovative approach to disrupt established cancer pathways could provide a paradigm shift in how the medical community approaches cancer treatment. By elucidating the role of mechanical signals in tumor biology, Roca-Cusachs’ team aims to uncover novel insights that may influence the field’s understanding of disease progression and treatment response.

If the project attains its objectives, the researchers harbor aspirations of establishing a spin-off company dedicated to advancing the development of these groundbreaking therapeutics to clinical applications. This could pave the way for the introduction of the first mechanoinhibitor drug, which would represent a pioneering advancement in the treatment of cancers characterized by mechanical stress responses, particularly focusing on breast and pancreatic cancer alongside other relevant pathologies such as fibrosis.

This ambitious journey encapsulates the essence of translational medicine and highlights the importance of bridging the gap between fundamental research and patient care. The potential benefits of the INTROPY project are manifold, not only for cancer patients but also for the broader landscape of disease treatment influenced by mechanical environments. As Roca-Cusachs and his team’s research progresses, it stands to elevate the discourse surrounding mechanotransduction and its multifaceted impacts on human health.

The ERC Proof of Concept Grant is not merely a financial boon but an attractive endorsement of the scientific inquiry rooted in the INTROPY project. It serves as a testament to the innovative thinking that can arise when researchers are empowered to transcend traditional research boundaries, venturing into realms of application and commercialization. Roca-Cusachs’ vision, coupled with his team’s relentless pursuit of knowledge and innovation, is a quintessential example of how academic research can evolve into significant contributions to societal health and well-being.

As the world grapples with the challenges posed by cancer, projects like INTROPY embody the hope that novel therapeutic strategies can alter the trajectory of disease management. The exploration of mechanotransduction pathways offers a fresh perspective on the intricate relationship between the physical properties of tissues and biological behavior. This understanding may lead to more precise and effective treatments tailored to the mechanical characteristics of tumors, thereby enhancing clinical outcomes for patients battling cancer.

The implications of this research could resonate well beyond oncology. The mechanisms underlying mechanotransduction are relevant to various other medical conditions involving altered tissue mechanics, such as cardiovascular diseases, musculoskeletal disorders, and fibrosis. The insights gained from the INTROPY project could, therefore, have a ripple effect, influencing therapeutic approaches across a spectrum of diseases characterized by dysfunctional mechanotransduction.

In summary, the journey of Pere Roca-Cusachs and his team signifies a remarkable intersection of innovative research and potential practical application. Through the INTROPY project, they are not only aiming to advance cancer therapy but also to foster a deeper understanding of the mechanical aspects of disease, potentially ushering in a new era of targeted therapies for various biomedical challenges.

Subject of Research: Mechanotransduction pathways in cancer therapy
Article Title: Innovative Study Seeks to Inhibit Mechanotransduction as a Novel Strategy for Cancer Treatment
News Publication Date: [To be filled]
Web References: [To be filled]
References: [To be filled]
Image Credits: Credit: Institute for Bioengineering of Catalonia (IBEC)
Keywords: Mechanotransduction, cancer therapy, breast cancer, pancreatic cancer, fibrosis, ERC Proof of Concept Grant.